scholarly journals Acupuncture Improves Certain Aspects of Sleep in Hematopoietic Stem Cell Transplantation Patients: a Randomized Controlled Trial

2021 ◽  
Author(s):  
Sarah El Iskandarani ◽  
Lingyun Sun ◽  
Susan Qing Li ◽  
Gloria Pereira ◽  
Sergio Giralt ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Sleep Quality ◽  
Controlled Trial ◽  
Sleep Onset ◽  
Sleep Efficiency ◽  
Sleep Onset Latency ◽  
Onset Latency ◽  
Hematopoietic Stem

Abstract Background High-dose chemotherapy followed by hematopoietic stem cell transplantation (HSCT) is associated with a high symptom burden including decrease in sleep quality. We conducted a randomized sham-controlled trial (#NCT01811862) to study the effect of acupuncture on sleep quality during HSCT. Methods Adult multiple myeloma patients undergoing inpatient and outpatient autologous HSCT were randomized to receive either true or sham acupuncture once daily for 5 days starting the day after chemotherapy. Sleep onset, total sleep time, sleep efficiency percentage, and sleep-onset latency time were assessed using an Actigraphy Sleep Monitor. A multi-variate regression analysis was conducted to compare the average area-under-the-curve of five acupuncture intervention days for each sleep outcome between groups, adjusted by baseline score and inpatient or outpatient chemotherapy stratum. Results Over 32 months, 63 patients were enrolled. Participants undergoing true acupuncture experienced a significant improvement in sleep efficiency when compared to sham (-6.70, 95% CI -13.15, -0.25, p=0.042). Subgroup analysis showed that the improvement is more prominent in the inpatient setting (-9.62, 95% CI -18.76, -0.47, p=0.040). True acupuncture produced noticeable yet non-significant improvement in sleep-onset latency times. Between-group differences in other sleep related variables were not statistically significant. Conclusion Our data suggest that true acupuncture may improve certain aspects of sleep, including sleep efficiency and possibly sleep-onset latency, in multiple myeloma patients undergoing HSCT. By studying patient reported outcomes in future larger scale studies, acupuncture’s role in improving sleep quality during HSCT treatment can be further elucidated.

Utility of Activity Monitors and Thermometry in Assessing Sleep Stages and Sleep Quality

2018 ◽  
Vol 1 (3) ◽  
pp. 108-121
Author(s):  
Natashia Swalve ◽  
Brianna Harfmann ◽  
John Mitrzyk ◽  
Alexander H. K. Montoye
Keyword(s):  
Sleep Quality ◽  
Skin Temperature ◽  
Sleep Stage ◽  
Sleep Onset ◽  
Sleep Efficiency ◽  
Sleep Stages ◽  
Sleep Onset Latency ◽  
Onset Latency ◽  
Activity Monitors ◽  
Research Grade

Activity monitors provide an inexpensive and convenient way to measure sleep, yet relatively few studies have been conducted to validate the use of these devices in examining measures of sleep quality or sleep stages and if other measures, such as thermometry, could inform their accuracy. The purpose of this study was to compare one research-grade and four consumer-grade activity monitors on measures of sleep quality (sleep efficiency, sleep onset latency, and wake after sleep onset) and sleep stages (awake, sleep, light, deep, REM) against an electroencephalography criterion. The use of a skin temperature device was also explored to ascertain whether skin temperature monitoring may provide additional data to increase the accuracy of sleep determination. Twenty adults stayed overnight in a sleep laboratory during which sleep was assessed using electroencephalography and compared to data concurrently collected by five activity monitors (research-grade: ActiGraph GT9X Link; consumer-grade: Fitbit Charge HR, Fitbit Flex, Jawbone UP4, Misfit Flash) and a skin temperature sensor (iButton). The majority of the consumer-grade devices overestimated total sleep time and sleep efficiency while underestimating sleep onset latency, wake after sleep onset, and number of awakenings during the night, with similar results being seen in the research-grade device. The Jawbone UP4 performed better than both the consumer- and research-grade devices, having high levels of agreement overall and in epoch-by-epoch sleep stage data. Changes in temperature were moderately correlated with sleep stages, suggesting that addition of skin temperature could increase the validity of activity monitors in sleep measurement.

Actigraphy assessment of sleep quality among patients with acute myeloid leukaemia during induction chemotherapy

2018 ◽  
Vol 8 (3) ◽  
pp. 274-277 ◽  
Author(s):  
Chi-Fu Jeffrey Yang ◽  
Kelli Aibel ◽  
Ryan Meyerhoff ◽  
Frances Wang ◽  
David Harpole ◽  
...  
Keyword(s):  
Acute Myeloid Leukaemia ◽  
Sleep Quality ◽  
Myeloid Leukaemia ◽  
Induction Chemotherapy ◽  
Sleep Onset ◽  
Sleep Efficiency ◽  
Poor Sleep ◽  
Sleep Onset Latency ◽  
Onset Latency ◽  
Acute Myeloid

ObjectivesPatients receiving induction chemotherapy for acute myeloid leukaemia (AML) anecdotally describe poor sleep, but sleep disturbances have not been well-characterised in this population. We aimed to test the feasibility of measuring sleep quality in AML inpatients using a wearable actigraphy device.MethodsUsing the Actigraph GT3X ‘watch’, we assessed the total sleep time, sleep onset latency, wake after sleep onset, number of awakenings after sleep onset and sleep efficiency for inpatients with AML receiving induction chemotherapy. We assessed patient self-reported sleep quality using the Pittsburgh Sleep Quality Index (PSQI).ResultsOf the 12 patients enrolled, 11 completed all actigraphy and PSQI assessments, demonstrating feasibility. Patients wore the Actigraph device for a mean (SD) of 15.92 (8.3) days, and actigraphy measures suggested poor sleep. Patients had a median average awakening length of 6.92 min, a median number of awakenings after sleep onset of 4 and a median sleep onset latency of 10.8 min. Actual median sleep efficiency (0.91) was high, suggesting that patients’ poor sleep was not due to insomnia but perhaps due to interruptions, such as administration of medications, lab draws and vital sign measurements.ConclusionsCollection of sleep quality data among inpatients with AML via a wearable actigraphy device is feasible. AML inpatients appear to have poor sleep quality and quantity, suggesting that sleep issues represent an area of unmet supportive care needs in AML. Further research in this areas is needed to inform the development of interventions to improve sleep duration and quality in hospitalised patients with AML.

scholarly journals Tandem Autologous Hematopoietic Stem Cell Transplantation in Very Young Patients with Multiple Myeloma

2020 ◽  
Vol 09 (04) ◽  
pp. 233-235
Author(s):  
Rahul Naithani ◽  
Nitin Dayal ◽  
Reeta Rai
Keyword(s):  
Multiple Myeloma ◽  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Young Patients ◽  
Cell Transplant ◽  
Hematopoietic Stem ◽  
Platelet Recovery

Abstract Introduction Multiple myeloma (MM) in very young patients is uncommon, and no treatment guidelines exist for these patients. Patients and Methods We performed a retrospective analysis of five very young myeloma patients who underwent tandem autologous hematopoietic stem cell transplantation (HSCT). Results The median age was 37 years (range = 34–40 years). A median of two leukapheresis was performed (range = 1–4). The median number of hematopoietic stem cells collected was 5.4 × 106/kg (4.4–8.2 × 106/kg). During first transplant, four patients received melphalan of 200 mg/m2 and one patient received melphalan of 140 mg/m2 (due to renal failure) as conditioning regimen. Second transplant conditioning was melphalan of 200 mg/m2 for one patient and melphalan of 140 mg/m2 for remaining four patients. Two patients were in complete remission, and two were in very good partial remission and one patient progressed to active disease at the time of tandem autologous bone marrow transplant. All patients developed significant mucositis. Neutrophil and platelet recovery was longer in tandem autologous hematopoietic stem cell transplant. More viral infections were seen in tandem transplant. Day 30 and day 100 mortality was nil. Conclusion We present data on tandem autologous HSCTs in very young patients with MM in India. Responses continued to improve in this small series.

166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials

Blood ◽  
2003 ◽  
Vol 102 (7) ◽  
pp. 2684-2691 ◽  
Author(s):  
Sergio Giralt ◽  
William Bensinger ◽  
Mark Goodman ◽  
Donald Podoloff ◽  
Janet Eary ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Bone Marrow ◽  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Phase 1 ◽  
High Dose ◽  
Two Phase ◽  
Hematopoietic Stem

Abstract Holmium-166 1, 4, 7, 10-tetraazcyclododecane-1, 4, 7, 10-tetramethylenephosphonate (166Ho-DOTMP) is a radiotherapeutic that localizes specifically to the skeleton and can deliver high-dose radiation to the bone and bone marrow. In patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation two phase 1/2 dose-escalation studies of high-dose 166Ho-DOTMP plus melphalan were conducted. Patients received a 30 mCi (1.110 Gbq) tracer dose of 166Ho-DOTMP to assess skeletal uptake and to calculate a patient-specific therapeutic dose to deliver a nominal radiation dose of 20, 30, or 40 Gy to the bone marrow. A total of 83 patients received a therapeutic dose of 166Ho-DOTMP followed by autologous hematopoietic stem cell transplantation 6 to 10 days later. Of the patients, 81 had rapid and sustained hematologic recovery, and 2 died from infection before day 60. No grades 3 to 4 nonhematologic toxicities were reported within the first 60 days. There were 27 patients who experienced grades 2 to 3 hemorrhagic cystitis, only 1 of whom had received continuous bladder irrigation. There were 7 patients who experienced complications considered to be caused by severe thrombotic microangiopathy (TMA). No cases of severe TMA were reported in patients receiving in 166Ho-DOMTP doses lower than 30 Gy. Approximately 30% of patients experienced grades 2 to 4 renal toxicity, usually at doses targeting more than 40 Gy to the bone marrow. Complete remission was achieved in 29 (35%) of evaluable patients. With a minimum follow-up of 23 months, the median survival had not been reached and the median event-free survival was 22 months. 166Ho-DOTMP is a promising therapy for patients with multiple myeloma and merits further evaluation. (Blood. 2003;102:2684-2691)

Sign in / Sign up

Export Citation Format

Share Document